Clinical Trials

The purpose of this study is to demonstrate the safety and effectiveness of   CLS-TA ("suprachoroidal CLS-TA") used in combination with an anti-VEGF agent ("intravitreal anti-VEGF agent") in subjects with retinal vein occlusion (RVO).

SCORE2 is a multicenter, prospective, randomized, phase III clinical trial in which all participants enrolled will be followed for up to 2.5 years. SCORE2 is designed as a non-inferiority trial, with study eyes randomized to intravitreal bevacizumab (1.25 mg) every 4 weeks vs. intravitreal aflibercept (2.0 mg) every 4 weeks. SCORE2 aims to determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema associated with central retinal vein occlusion (CRVO), with the primary outcome of visual acuity measured at Month 6.

SCORE2 is a multicenter, prospective, randomized, phase III clinical trial in which all participants enrolled will be followed for 12 months. SCORE2 is designed as a non-inferiority trial, with study eyes randomized to intravitreal bevacizumab (1.25 mg) every 4 weeks vs. intravitreal aflibercept (2.0 mg) every 4 weeks. SCORE2 aims to determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema associated with central retinal vein occlusion (CRVO), with the primary outcome of visual acuity measured at Month 6.

The goal of this study is to update the incidence of perioperative vision loss from ischemic optic neuropathy, retinal vein or artery occlusion, and cortical blindness from all non-ocular general anesthesia surgery, including robotic surgery, that has been performed at Mayo Clinic from 2003-2012. The study will also aim to determine the visual acuity outcomes following perioperative vision loss.